Loading...
Ibrutinib (PCI-32765) in Chronic Lymphocytic Leukemia
B-cell receptor (BCR) signaling is essential for chronic lymphocytic leukemia (CLL) cell survival. Many kinases in the BCR signaling pathway are currently being studied as potential therapeutic targets. These include Lyn, Syk, PI3 and Bruton tyrosine (BTK). Ibrutinib (PCI-32765) is a novel first-in-...
Na minha lista:
| Udgivet i: | Hematol Oncol Clin North Am |
|---|---|
| Main Authors: | , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
2013
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4449150/ https://ncbi.nlm.nih.gov/pubmed/23915749 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.hoc.2013.01.006 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|